



LKT Laboratories, Inc.

OSI-027

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID O7332

CAS No. 936890-98-1

Chemical Name

Synonym

Formula $C_{21}H_{22}N_6O_3$

Formula Wt. 406.44

Melting Point


Purity $\geq 99\%$

Solubility DMSO 18 mg/mL (44.28 mM)
Water Insoluble
Ethanol Insoluble

Store Temp 4° C

Ship Temp Ambient

Description OSI-027 is an inhibitor of mTORC1/2 that exhibits anticancer chemotherapeutic activity. In vitro, OSI0027 inhibits phosphorylation of downstream target Akt, inhibiting cell proliferation in breast cancer cells. OSI-027 also induces apoptosis in several lymphoid cell lines including mantle cell lymphoma, acute lymphocytic leukemia (ALL), and others. In animal models of cancer, this compound inhibits tumor growth.



Bulk quantities available upon request

Product ID	Size
O7332	1 mg
O7332	5 mg
O7332	10 mg

References Li H, Lin J, Wang X, et al. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer. *Breast Cancer Res Treat.* 2012 Aug;134(3):1057-66. PMID: 22476852.

Gupta M, Hendrickson AE, Yun SS, et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. *Blood.* 2012 Jan 12;119(2):476-87. PMID: 22080480.

Falcon BL, Barr S, Gokhale PC, et al. Reduced VEGF production, angiogenesis, and vascular regrowth contribute to the antitumor properties of dual mTORC1/mTORC2 inhibitors. *Cancer Res.* 2011 Mar 1;71(5):1573-83. PMID: 21363918.

Vakana E, Sassano A, Plataniias LC. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. *Autophagy.* 2010 Oct;6(7):966-7. PMID: 20699667.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.